Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kura Oncology

6.06
-0.1400-2.26%
Post-market: 6.250.1900+3.14%19:08 EDT
Volume:1.05M
Turnover:6.45M
Market Cap:524.64M
PE:-2.90
High:6.26
Open:6.19
Low:6.01
Close:6.20
Loading ...

Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting

GlobeNewswire
·
03 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Natgas companies, UnitedHealth, Cactus

Reuters
·
03 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Lyra Therapeutics, Church & Dwight, Applied Digital

Reuters
·
02 Jun

Kura Oncology Shares up 7.5% After FDA Accepts Marketing Application for Blood Cancer Drug

THOMSON REUTERS
·
02 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Xilio Therapeutics, Red Rock Resorts, Kymera

Reuters
·
02 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Moderna, Blueprint Medicines, Boeing

Reuters
·
02 Jun

BUZZ-Kura Oncology gains as FDA accepts marketing application for blood cancer drug

Reuters
·
02 Jun

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults With Relapsed or Refractory Npm1-Mutant Aml

THOMSON REUTERS
·
02 Jun

Promising Trial Data and Strategic Focus Drive Buy Rating for Kura Oncology

TIPRANKS
·
23 May

TD Cowen Sticks to Their Buy Rating for Kura Oncology (KURA)

TIPRANKS
·
23 May

BTIG Reaffirms Their Hold Rating on Kura Oncology (KURA)

TIPRANKS
·
23 May

Kura Oncology (KURA) Receives a Buy from Barclays

TIPRANKS
·
23 May

Kathleen Ford, Chief Operating Officer, Reports Disposal of Kura Oncology Inc. Common Shares

Reuters
·
20 May

Kura Oncology Is Maintained at Outperform by Mizuho

Dow Jones
·
20 May

Kura Oncology price target lowered to $30 from $32 at Mizuho

TIPRANKS
·
19 May

Analysts Offer Insights on Healthcare Companies: scPharmaceuticals (SCPH), 10x Genomics (TXG) and Kura Oncology (KURA)

TIPRANKS
·
19 May

Mizuho Adjusts Price Target on Kura Oncology to $30 From $32, Maintains Outperform Rating

MT Newswires Live
·
16 May

Kura Oncology: Promising Clinical Trials and Stable Financials Justify Buy Rating

TIPRANKS
·
15 May

Kura Oncology Is Maintained at Overweight by Barclays

Dow Jones
·
02 May

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
02 May